Novavax (NVAX) EPS (Weighted Average and Diluted) (2019 - 2026)
Novavax (NVAX) recorded quarterly EPS (Weighted Average and Diluted) of -$0.06 in Q1 2026, down 220.0% quarter-over-quarter from $0.05 in Q4 2025, and down 102.05% on a YoY basis from $2.93 in Q1 2025.
Novavax (NVAX) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Novavax's EPS (Weighted Average and Diluted) history runs 8 years deep, the most recent figure standing at -$0.06 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) fell 102.05% year-over-year to -$0.06; the TTM figure through Mar 2026 stood at -$0.64 (down 124.24% YoY), while the FY2025 annual figure was $2.58, up 309.76% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.06 for Q1 2026 at Novavax, down from $0.05 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.93 in Q1 2025 to a low of -$6.53 in Q2 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.77 across 5 years, with a median of -$0.76 in 2024.
- The sharpest annual moves came in 2023 and 2025: EPS (Weighted Average and Diluted) plunged 233.2% in 2023, then soared 379.05% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$2.29 in 2022, then soared by 35.81% to -$1.47 in 2023, then jumped by 64.63% to -$0.52 in 2024, then jumped by 109.62% to $0.05 in 2025, then sank by 220.0% to -$0.06 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.06 (Q1 2026), $0.05 (Q4 2025), and -$1.25 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Novavax | 1.49 Bn | 931.98 Mn | 108.82 Mn | -0.06 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.06 |
| Dec 31, 2025 | 0.05 |
| Sep 30, 2025 | -1.25 |
| Jun 30, 2025 | 0.62 |
| Mar 31, 2025 | 2.93 |
| Dec 31, 2024 | -0.52 |
| Sep 30, 2024 | -0.76 |
| Jun 30, 2024 | 0.99 |
| Mar 31, 2024 | -1.05 |
| Dec 31, 2023 | -1.47 |
| Sep 30, 2023 | -1.26 |
| Jun 30, 2023 | 0.58 |
| Mar 31, 2023 | -3.41 |
| Dec 31, 2022 | -2.29 |
| Sep 30, 2022 | -2.15 |
| Jun 30, 2022 | -6.53 |
| Mar 31, 2022 | 2.56 |
| Dec 31, 2021 | -11.31 |
| Sep 30, 2021 | -4.31 |
| Jun 30, 2021 | -4.75 |